The antibiotic, called Zerbaxa, is the first new antibiotic approved in the U.S. under the Generating Antibiotic Incentives Now Act to treat Gram-negative bacteria.
“Today is an important day for patients, and we are very pleased to arm physicians with Zerbaxa in the battle against Gram-negative bacteria, where few treatment options exist,” said Robert Perez, president and COO of Cubist.
This is the fourth new antibacterial drug approved by the FDA this year, and the second one from Cubist. That makes it the first time this century a company has delivered two new FDA-approved antibiotics in one year.
More articles on antibiotics:
Patients don’t understand the risks of unnecessary antibiotics
The easiest way to reduce antibiotic prescribing in children’s hospitals
Merck to acquire antibiotic developer Cubist for $9.5B
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
